-
-
-
-
-
-
-
Baird on Enanta Pharmaceuticals (ENTA): 'No change to outlook on 2026 update'
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA)
-
-
-
-
-
-
-
Enanta Pharma's (ENTA) Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Vi
-
-
-
-
-
-
-
Enanta Pharma (ENTA) Tops Q1 EPS by 22c
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA)
-
-
-
-
420,196 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

